Sangamo Therapeutics CEO and leadership

Sandy Macrae is a Board Member at 4D Pharma and is based in Brisbane, California. She has worked as President/CEO at SANGAMO THERAPEUTICS, INC; Board Member at SANGAMO THERAPEUTICS, INC; and Group Director, Neuroscience and Gastroenterology Therapeutic Unit at SmithKline Beecham Corporation. Alexander works or has worked as Senior VP:Emerging Markets at GSK and MEMBER at Royal College of Physicians. She studied at University of Glasgow between 1979 and 1986, Columbia University, and King's College Cambridge.

D. Mark McClung is an EVP and Chief Business Officer at SANGAMO THERAPEUTICS, INC.

James R. Meyers has served as a member of Sangamo’s Board of Directors since November 2019. He has over 30 years of commercial leadership experience in the biotechnology industry. Mr. Meyers worked at Gilead from 1996 until his retirement in February 2018. Most recently, he served as Gilead’s Executive Vice President of Worldwide Commercial Operations, where he was responsible for global commercial activities, including pricing and market access in North America, Europe, Middle East, Australia and Japan. At Gilead, he successfully led several important product launches in the HIV and hepatitis C therapeutic areas. Prior to Gilead, Mr. Meyers held positions of increasing responsibility with Zeneca Pharmaceuticals and Astra USA. He currently serves on the Board of Directors of two public companies, Arbutus Biopharma Corp. and CytomX Therapeutics, and he remains an active advisor to several major biopharmaceutical companies. Mr. Meyers holds a B.S. in Economics from Boston College.

Robert F. Carey is a President and Chief Operating Officer, Acelyrin, Inc. at SANGAMO THERAPEUTICS, INC.

Bettina Cockroft, M.D., M.B.A., has served as Senior Vice President and Chief Medical Officer since September 2019 and oversees all clinical development activities and operations. She has over 20 years of experience in the biopharmaceutical industry and has worked across multiple therapeutic areas and led programs in several countries. Prior to joining Sangamo, Dr. Cockroft served on the senior leadership team at Cytokinetics, Inc., where she was responsible for clinical development of fast skeletal muscle troponin activators in diseases such as Amyotrophic Lateral Sclerosis and Spinal Muscular Atrophy. Before that, Dr. Cockroft served as Chief Medical Officer of Auris Medical AG, where she led and grew the clinical development team responsible for two Phase 3 programs. Dr. Cockroft also held roles of increasing responsibility at Merck Serono S.A., Novartis Consumer Health and Menarini Ricerche earlier in her career.

Jaspreet Jas Gill are a SVP & Chief Quality Officer at SANGAMO THERAPEUTICS, INC.

Sandy Macrae is a Board Member at 4D Pharma and is based in Brisbane, California. She has worked as President/CEO at SANGAMO THERAPEUTICS, INC; Board Member at SANGAMO THERAPEUTICS, INC; and Group Director, Neuroscience and Gastroenterology Therapeutic Unit at SmithKline Beecham Corporation. Alexander works or has worked as Senior VP:Emerging Markets at GSK and MEMBER at Royal College of Physicians. She studied at University of Glasgow between 1979 and 1986, Columbia University, and King's College Cambridge.

James R. Meyers has served as a member of Sangamo’s Board of Directors since November 2019. He has over 30 years of commercial leadership experience in the biotechnology industry. Mr. Meyers worked at Gilead from 1996 until his retirement in February 2018. Most recently, he served as Gilead’s Executive Vice President of Worldwide Commercial Operations, where he was responsible for global commercial activities, including pricing and market access in North America, Europe, Middle East, Australia and Japan. At Gilead, he successfully led several important product launches in the HIV and hepatitis C therapeutic areas. Prior to Gilead, Mr. Meyers held positions of increasing responsibility with Zeneca Pharmaceuticals and Astra USA. He currently serves on the Board of Directors of two public companies, Arbutus Biopharma Corp. and CytomX Therapeutics, and he remains an active advisor to several major biopharmaceutical companies. Mr. Meyers holds a B.S. in Economics from Boston College.

Robert F. Carey is a President and Chief Operating Officer, Acelyrin, Inc. at SANGAMO THERAPEUTICS, INC.